Karyopharm announces presentation of interim data from phase 2 study of single-agent eltanexor in relapsed/refractory (r/r) higher-risk myelodysplastic neoplasms (mds) at 17th international congress on mds

– relapsed/refractory mds patients achieved median overall survival of 8.7 months – –  historically, median overall survival in this hard to treat patient population is only 4-6 months 1,2 – – results indicate potential single agent activity of eltanexor in patients with r/r mds – newton, mass. , may 3, 2023 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced interim data from the phase 2 portion of the open-label phase 1/2 study of single-agent eltanexor in patients with higher r/r myelodysplastic neoplasms.
KPTI Ratings Summary
KPTI Quant Ranking